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Abstract  
There are many approaches to assessing platelet reactivity and many uses for such 
measurements. Initially, measurements were based on the ability of platelets separated 
from other blood cells to aggregate together following activation with an appropriate 
‘aggregating agent’. Later, measurements of platelet aggregation in blood itself were 
performed, and this led to a point-of-care approach to platelet function testing. 
Measurement of secretory activity through the appearance of the activation marker P-
selectin on platelets now provides an alternative approach, which enables remote 
testing. Measurement of vasodilator-stimulated phosphoprotein phosphorylation is also 
moving toward application in situations remote from the testing laboratory. Here we 
provide an overview of the various approaches that are now available, assess their 
advantages and disadvantages, and describe some of the clinical situations in which 
they are being used. 
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Platelet reactivity is a broad term indicating the degree of the response of blood 
platelets to an external stimulus, usually an ‘aggregating agent’. Platelet reactivity can 
be measured in many different ways and the purpose of this review is to summarize the 
approaches, with an emphasis on the newer approaches that are becoming available. 
 
Platelets play an important role in the hemostatic process [1,2]. They contribute to the 
formation of a hemostatic plug that serves to prevent blood loss from injured blood 
vessels. The hemostatic plug contains thousands of platelets that have aggregated 
together within a network of fibrin. However, platelets also contribute to the generation 
of a thrombotic mass in a coronary or cerebral artery or in an artificial stent leading to 
blockage and resulting in conditions such as heart attack, stroke and stent thrombosis 
[3,4]. A thrombus is also composed of platelet aggregates within a fibrin network. 
So thrombus formation can thus be considered to be hemostasis in the wrong place. 
 
It is believed that aggregating agents that are newly released into the arterial circulation 
or become newly exposed on damaged tissue or on atherosclerotic plaque bring about 
the platelet aggregation that contributes to the participation of platelets in hemostasis 
and thrombosis. Some important aggregating agents are collagen, thrombin, ADP and 
thromboxane A2 (TXA2). These activate platelets through receptors for these agents on 
the platelet surface. Measurements of platelet reactivity have served to quantify the 
effects of these and other aggregating agents on platelets. They have also served to 
quantify the degree of inhibition of platelet activity brought about by pharmacological 
agents known as ‘antiplatelet agents’, some of which are now used routinely as 
medicines [5]. 
 
There is a general concept that a pronounced platelet response to an aggregating agent 
is associated with an increased risk of thrombosis and that a low platelet response is 
associated with bleeding and bruising. Identification of congenital deficiencies in 
platelet function has helped explain bleeding diatheses and the importance of platelet 
function in the hemostatic process [6]. 
 
Patients with high residual platelet activity despite treatment with antiplatelet agents 
are at higher risk of future thrombotic events [7]. Also, excessive inhibition of platelet 
reactivity by antiplatelet agents can be associated with excessive bleeding with 
implications for surgical interventions. Consequently, there is now the concept of using 
measurements of platelet reactivity to identify a ‘therapeutic window’ in patients, so as 
to reduce the risk of a thrombotic event without increasing the risk of bleeding [8–10]. 
 
Approaches to assessment of platelet reactivity 
 
Many years ago, it was discovered that adding ADP to platelet-rich plasma (PRP) caused 
platelets to clump together [11]. PRP is obtained when fresh blood, to which an 
anticoagulant such as sodium citrate has been added to stop the blood from clotting, is 
centrifuged slowly for about 10 min to remove the red cells and white cells. Within a 
few seconds of adding ADP or indeed any other aggregating agent to a stirred sample of 
PRP, the turbidity starts to reduce and within a few minutes the PRP becomes virtually 
clear. This is a consequence of the individual platelets clumping together to form 
aggregates of nearly all the platelets that are present. The clumps become so large that 
they can be seen easily with the naked eye.  
 
Sometimes, the platelet aggregation is irreversible and sometimes it is reversible, in 
that the aggregation is followed by disaggregation. The type of response is dependent 
on the absence or presence of pathology in the volunteer or patient being investigated. 
For example, it can be reduced or absent in patients with bleeding disorders and can be 
excessive in some patients who are at high risk of thrombosis. It is also dependant on 
the type and concentration of the aggregating agent used, and on the presence or 
otherwise of a drug designed to inhibit the platelet response. 
 
The ‘clearing’ of the PRP as aggregation progresses became the basis for measurement 
of platelet aggregation, hence ‘light transmission aggregometry (LTA)’ or ‘turbidimetry’ 
in which the ‘clearing’ of the PRP was monitored by detecting the amount of light 
transmitted through the stirred sample of PRP. The equipment that is used for stirring 
the PRP and for monitoring the changes in light transmission that occur is known as an 
aggregometer. LTA is still referred to as the ‘gold standard’ for measurements of platelet 
aggregation or platelet reactivity [12]. This is despite additional approaches to 
measurement of platelet aggregation that have appeared over the years.  
 
Measurement of platelet aggregation as a means of assessing platelet reactivity is 
attractive in that it is the formation of clumps of platelets (platelet aggregates) in 
response to an external stimulus that is a major contributor to the formation of a 
hemostatic plug formation or a thrombus. The aggregated platelets together with fibrin, 
the end product of the coagulation cascade, provide structure and stability.  
 
The main external stimuli involved in hemostatic plug and thrombus formation are 
collagen and thrombin. Collagen is exposed on damaged or diseased blood vessels. 
Thrombin forms as a consequence of tissue factor exposure and also of platelet 
adherence to leukocytes to produce platelet–leukocyte conjugates that display tissue 
factor. Interaction with collagen or thrombin also leads to synthesis of TXA2 from 
arachidonic acid (AA) liberated from phospholipids within the activated platelets, and 
also secretion of the contents of storage granules that include ADP. The TXA2 and the 
ADP contribute further to the platelet aggregation [2,5]. 
 
The problems with measurement of platelet aggregation using the LTA approach are 
threefold. First, the measurements are made in PRP; this is considered to be less 
physiological compared with blood itself. Second, the number of platelets in the PRP 
(and hence the turbidity of the sample) varies from patient to patient. Third, the 
approach requires prompt access to a laboratory with the appropriate equipment and 
expertise for the measurements to be performed.  
 
Newer approaches to measuring platelet aggregation focus on whole blood, rather than 
PRP, and include Multiplate Electrode Aggregometry (MEA; a type of impedance 
aggregometry), VerifyNow (a turbidimetric approach that involves adding fibrinogen 
coated beads to whole blood) and approaches based on platelet counting. 
 
Platelet aggregation is only one platelet response to an external stimulus. Platelets are 
complex organelles present in blood in high numbers that, as already mentioned, can be 
induced to synthesize molecules such as TXA2 and to secrete the contents of 
intracellular granules including ADP. P-selectin, that forms part intracellular granules 
known as α-granules, appears on the platelet surface following platelet activation and 
mediates platelet–leukocyte conjugate formation leading to enhanced generation of 
thrombin and subsequent fibrin formation. In addition, following an external stimulus 
there are biochemical changes in platelets that can be quantitated, such as 
phosphorylation of vasodilator-stimulated phosphoprotein (VASP). Some of these 
approaches have the advantage of being performed remotely from the testing 
laboratory with no need for specialist equipment or technical expertise close at hand. 
 
Methods based on measurements of platelet aggregation 
 
Light transmission aggregometry 
 
Although LTA can no longer be considered a novel strategy, it formed the basis for the 
methods that came later on, and as previously mentioned, is still considered to be the 
gold standard for measurement of platelet reactivity. The aggregating agent under 
investigation is added to a stirred sample of PRP in an aggregometer, and the 
aggregation is quantitated by the increase in light transmittance that occurs. Typical 
aggregating agents tested include ADP, epinephrine, collagen, AA and thrombin. With 
regard to thrombin, this is often replaced by a thrombin receptor activation peptide that 
has the advantage of activating the platelet without also initiating the coagulation 
cascade by converting fibrinogen to fibrin. The antibiotic, ristocetin is sometimes used 
for some diagnostic purposes. 
 
For many years, the test has been used to look for defects in platelet aggregation that 
might explain enhanced bruising or bleeding in a patient. For example, deficiencies in 
the aggregation response to ADP and most other aggregating agents are indicative of a 
condition known as Glanzmann’s thrombasthenia brought about by absent or abnormal 
glycoproteins (GPs) known as GPIIb and GPIIIa on platelets; the GPs need to be present 
as a complex (the GPIIb/IIIa complex) for platelet aggregation to occur. Platelet 
activation is accompanied by a rearrangement in the 3D structure of GPIIb/IIIa such 
that it binds fibrinogen, which then links adjacent-activated platelets together. An 
absent response to the antibiotic ristocetin is indicative of the Bernard–Soulier 
syndrome, brought about by the absence or change in another GP complex GPIb/IX/V 
that is needed for a normal interaction of platelets with the von Willebrand factor in 
blood plasma; interaction with the von Willebrand factor forms one of the mechanisms 
through which platelets adhere to exposed collagen [13]. 
 
 Numerous studies have identified the pharmacological effects of different agents and 
drugs on platelets. For example, aspirin inhibits aggregation brought about by AA as it 
blocks the cyclo-oxygenase involved in converting this into TXA2. Clopidogrel and newer 
P2Y12 antagonists, such as prasugrel, ticagrelor and cangrelor reduce the extent of the 
platelet aggregation brought about by ADP by interfering with the ability of ADP to 
interact with P2Y12 receptors on the platelet surface [5].  
 
An example of the use of LTA to assess the impact of different doses of the newly 
developed drug, AZD6140, in comparison with a standard dose of clopidogrel in 
patients with atherosclerosis is the DISPERSE study [14]. This is mentioned specifically 
here because this was a landmark study that clearly demonstrated differences in the 
rate of onset of inhibition of platelet aggregation by a new orally administered P2Y12 
antagonist compared with clopidogrel, differences in degree of inhibition of platelet 
aggregation, and also differences in the rate of recovery when the drug was withdrawn. 
The drug in question became known later as ticagrelor. Both prasugrel and ticagrelor 
are now deemed to be much more effective overall than clopidogrel as inhibitors of 
platelet aggregation and this translates into more effective antithrombotic therapy, 
albeit with an increased risk of depressed hemostasis and thus, an increased risk of 
bleeding [7].  
 
Some antiplatelet agents appear to be much more effective as inhibitors of platelet 
aggregation after administration to some patients compared with others, and it is this 
variability in effectiveness that may make the drug clopidogrel less effective as a 
medicine compared with other P2Y12 antagonists. Despite this, clopidogrel is still widely 
used as a means of treating patients with a high risk of thrombosis [15]. One reason for 
variability in the patient response to clopidogrel is that there are genetic differences in 
the CYP450 enzymes responsible for converting clopidogrel (which is a prodrug) into 
its active metabolite [16,17]. Others may include accelerated platelet turnover, 
upregulation of the P2Y12 pathways, high baseline platelet reactivity, poor compliance, 
underdosing and drug–drug interactions [18]. Many clinical studies have demonstrated 
that high residual platelet aggregation in response to ADP, despite treatment with the 
P2Y12 antagonist clopidogrel, is associated with further ischemic outcomes [7,16]. 
 
As stated above, the newer versions of this class of drug are much less variable in their 
effectiveness as inhibitors of platelet reactivity. The frequency of ‘nonresponse’ to 
aspirin, another drug that is very widely used in patients with atherosclerosis, as judged 
by a lack of effect of the drug on AA-induced platelet aggregation, is also much lower 
than that seen with clopidogrel [19].  
 
Usually, LTA is used to study platelet aggregation in small samples of PRP stirred in an 
aggregometer. More recently, LTA has been successfully used in the Optimul Assay in 
which the effects of multiple platelet agonists have been tested in parallel in PRP 
obtained from patients with bleeding disorders. The approach involves agitating small 
volumes of PRP in a 96-well platelet with measurement of the changes in light 
absorbance using a platelet reader. The approach proved to be comparable with other 
testing procedures [20]. 
 
Multiplate electrode aggregometry 
 
Impedance aggregometry was introduced by Cardinal and Flower [21]. It is based on 
the measurement of the electrical resistance between two electrodes immersed in 
stirred whole blood. As platelets aggregate and bind to the electrodes, there is a change 
in electrical impedance that corresponds to the degree of aggregation that has occurred. 
A clear advantage of using whole blood rather than PRP is that a centrifugation step is 
not required, thus simplifying the measurement and opening up the possibility of a 
point-of-care approach to measurement of platelet reactivity.  
 
The version of impedance aggregometry that has been used most in recent years is MEA 
(Multiplate Analyzer, Roche, Munich, Germany), which uses two sets of electrode pairs, 
so that a double determination is performed on each sample to ensure measurement 
repeatability. The advantage compared with LTA is that the measurements are 
performed in blood rather than PRP. The main disadvantage is that, as for LTA, prompt 
access to a laboratory and appropriate expertise is still needed. 
 
In the literature, there are many positive examples of the use of MEA. For example, MEA 
was used to investigate the inherited bleeding disorder Glanzmann’s thrombasthenia 
where markedly reduced responses to a number of platelet-aggregating agents were 
evident, in the same way as seen with LTA [22,23]. The approach also proved as useful 
as LTA for measuring the degree of inhibition of platelet aggregation by the antiplatelet 
agents aspirin and clopidogrel in preoperative patients scheduled for elective cardiac 
surgery [24]. 
 
Clopidogrel is one of the most commonly used P2Y12 antagonists. However, as discussed 
above, the pharmacodynamics response varies with a significant number of patients 
presenting with high platelet reactivity despite the treatment. And as with 
measurements performed using LTA, high residual platelet reactivity as measured with 
MEA is associated with increased risk of further ischemic outcomes. The practical 
usefulness of the MEA approach was demonstrated in a study performed by 
Hazarbasanov et al. [25] in which MEA was used to identify patients undergoing a 
percutaneous coronary intervention (PCI) who still demonstrated high platelet 
reactivity despite treatment with clopidogrel; in this case, increasing the dose of 
clopidogrel seemed to bring about favourable outcomes. 
 
In another study, the MADONNA study, patients in one hospital received additional 
antiplatelet therapy (guided by investigations using the MEA) while those in another 
hospital did not. The study demonstrated the benefit of tailored antiplatelet therapy in 
that stent thrombosis and acute coronary syndrome occurred significantly less often in 
the guided group [26]. In another study, low platelet reactivity identified using the MEA 
seemed to be as effective as assessment of CYP450 variants in identifying patients 
undergoing coronary stent placement with an increased bleeding risk, although in this 
case the expected relationship between high platelet reactivity and stent thrombosis 
was not evident [27]. 
 
Currently, the benefit of MEA testing to guide treatment is being tested in the 
TROPICALACS trial that is investigating the clinical and health–economic impact of 
tailored antiplatelet therapies in PCI [28]. 
 
VerifyNow 
 
VerifyNow (Accumetrics, Inc, CA, USA) is a testing approach that is specifically used for 
point-of-care measurement of inhibition of platelet aggregation by aspirin, P2Y12 
antagonists such as clopidogel, and also antiplatelet agents known as GPIIb/IIIa 
antagonists. As with LTA and MEA, ADP is used to activate the platelet to monitor 
clopidogrel therapy, while AA is used to monitor aspirin therapy. A thrombin receptor 
activation peptide is used to monitor the effects of a GPIIb/IIIa antagonist. Following 
activation by the agonist, fibrinogen-coated beads are able to bind to the activated 
platelet through GPIIb/IIIa on the platelet surface to form an agglutinate and the 
resulting ‘clearing’ of the sample is measured by turbidimetry. The tests are fully 
automated for measurements made at the point of blood collection and there is no 
requirement for a specialized laboratory and/or specially trained expert personnel. 
 
As with LTA and MEA, the VerifyNow system has been used to demonstrate the 
prognostic significance of high residual platelet function in patients treated with 
clopidogrel. For example, a higher risk of stent thrombosis and myocardial infarction 
was evident in association with high residual platelet reactivity in the ADAPT-DES study 
[29]. In a further analysis of the same study, low residual platelet reactivity in 
clopidogrel treated patients was demonstrated to be associated with increased bleeding 
[30]. Low residual platelet reactivity was also shown to be associated with bleeding in a 
study of patients undergoing PCI [31]. In view of such findings, VerifyNow has also been 
tested as a means of predicting bleeding in clopidogrel-treated patients undergoing 
coronary artery bypass grafting and a relationship between lower platelet reactivity 
and increased bleeding has been established in two pilot studies that have been 
performed [32,33]. 
 
In view of higher rates of thrombotic consequences in patients with high residual 
platelet reactivity in clopidogrel-treated patients, two large studies were performed in 
which the intension was to use the VerifyNow system to demonstrate the benefit of 
adjusting antiplatelet therapy in patients undergoing PCI for stable coronary artery 
disease. Unfortunately, the GRAVITAS study did not demonstrate any reduction in 
serious cardiovascular outcomes in patients with high on-treatment platelet reactivity 
who received a higher dose of clopidogrel consequent to testing [34]. It has been argued 
that simply increasing the dose of clopidogrel is insufficient to achieve the effect that 
was desired, and that this is the main reason for the negative outcome of this study [35]. 
In the second study, TRIGGER-PCI, the more potent P2Y12 antagonist prasugrel was 
used in place of clopidogrel to effect greater inhibition of platelet function in patients 
with high residual platelet reactivity, but this trial also failed to meet the desired 
outcome. The study was terminated prematurely due to a lower than the expected event 
rate in the relatively low-risk patients who were recruited into this study [36]. 
 
Very recently, it was reported that VerifyNow testing to optimize treatment with 
prasugrel in elderly patients with acute coronary syndromes in the ANTARCTIC trial 
failed to provide any benefit in terms of a composite of cardiovascular death, 
myocardial infarction, stroke, stent thrombosis, urgent revascularization and bleeding 
complication at 1 year [37].  
 
More positively, clopidogrel non-responders identified using the VerifyNow system who 
then received the GPIIb/IIIa antagonist tirofiban in addition to standard therapy with 
aspirin and clopidogrel went on to experience fewer subsequent incidents of myocardial 
infarction [38,39]. 
 
Platelet counting 
 
When platelets aggregate together the number of single platelets in the blood falls and 
this fall in platelet number can be used as a measure of the extent of platelet 
aggregation that occurs. Platelet counting can be performed using a commercial whole 
blood cell counter that utilizes impedance counting technology, or using a flow 
cytometer [40]. The use of a fixative that stops the aggregation at the point at which a 
measurement is required, is an advantage if a platelet counting device is not 
immediately available for the counting to be performed [41,42,43].  
 
Plateletworks (Helena Laboratories, TX, USA) is an approach to the measurement of 
platelet aggregation in which platelets in blood are stimulated with ADP or collagen 
following which platelet counting is performed. Counts are compared with those prior 
to adding the aggregating agent. Immediate platelet counting is essential as no fixative is 
employed. The advantages over other approaches are that no sample preparation is 
needed; the measurements are performed on whole blood using preloaded baseline and 
platelet agonist tubes. Also it is a simple and rapid procedure and platelet count and 
aggregation results are available immediately provided a platelet counting device needs 
to be available. In a comparison with LTA, there was good agreement when used for 
monitoring the inhibitory effects of clopidogrel, although the necessity for immediate 
platelet counting was noted [44], which would have been due to the instability of the 
unfixed platelet aggregates in the blood. 
 
While not yet as widely used as other approaches to studying platelet reactivity in 
clinical situations, high on-treatment ADP-induced platelet reactivity in patients taking 
clopidogrel demonstrated using the Plateletworks approach has been shown to be 
predictive of subsequent myocardial infarction and of rehospitalization within 3 months 
of testing [45]. 
 
Adding a fixative to the blood at the precise point at which a measurement of platelet 
aggregation is required, has the advantage of introducing a period of time between 
experimentation and platelet counting that obviates the need for the immediate 
availability of a platelet counting device. It also provides the opportunity for remote 
testing with the actual platelet counting being performed up to several days after 
experimentation, thus opening up the number of different types of location for the 
testing.The fixative AGGFix (Platelet Solutions Ltd, Nottingham, UK) offers such an 
opportunity. 
 
A good example of the use of AGGFix to measure platelet aggregation remotely is a study 
that was performed in Iceland with the platelet counting performed in the UK. The 
circumstance was a clinical trial in which a new antiplatelet agent, an EP3 receptor 
antagonist, was administered to volunteers with and without clopidogrel or clopidogrel 
and aspirin, after which the effectiveness of the drugs as inhibitors of platelet 
aggregation was assessed [46]. More recently, AGGFix has also been used successfully 
for assessment of platelet aggregation using the platelet counting approach in blood 
placed in 96-well plates and also, in parallel, to assess the degree of platelet–leukocyte 
conjugate formation that occurred, assessed by flow cytometry [47]. 
 
Methods based on measurements of platelet activation markers 
 
As mentioned above, platelet aggregation is only one platelet response to an external 
stimulus. Synthesis of TXA2, release of ADP and the appearance on the platelet surface of 
activation markers such as P-selectin also provide means of assessing platelet reactivity. 
Measurements of TXB2, the stable breakdown product of TXA2 and also of TXA2 
metabolites have provided a direct means of assessing the activity of the 
cyclooxygenase in platelets and particularly the effect of aspirin on this. Measurements 
of secreted ADP have been performed in parallel with LTA in a device known as a 
lumiaggregometer and this has proved particularly useful in studies of defects in the 
platelet storage pool in patients leading to pronounced bruising and bleeding. Once 
again, however, the ready availability of specialist equipment and expertise are 
required. 
 
The appearance on the surface of platelets of markers of platelet activation can be 
demonstrated and quantitated using flow cytometry [48] and these include P-selectin 
that is translocated to the platelet surface from α-granules within platelets. Platelets can 
be activated in whole blood using an appropriate aggregating agent, either in blood that 
is left unstirred or that contains an additional agent such as EDTA to prevent platelet 
aggregation occurring. The amount of P-selectin on activated single platelets is then 
measured by flow cytometry. The use of a fixative added to the blood following platelet 
activation successfully extends the time between experimentation and P-selectin 
analysis to several days, thus allowing for remote platelet function testing. A useful 
fixative for this purpose that is commercially available is PAMFix (Platelet Solutions 
Ltd) [49]. 
 
There is now good progress in developing tests for particular purposes based on 
measurement of P-selectin and these include Aspirin Kits (for determining the effects of 
aspirin on platelet reactivity), P2Y12 kits (for determining the effects of drugs such as 
clopidogrel, prasugrel, ticagrelor and cangrelor on platelet reactivity) and kits for 
screening patients for evidence of platelet dysfunction without the need for referral to a 
specialist facility [49,50]. 
 
An assessment of platelet functional defects in patients with easy bruising and bleeding 
based on the appearance of activation markers on platelets was performed as part of 
the Genotyping and Phenotyping of Platelets study. In this study, both P-selectin (as a 
marker of α-granule secretion) and CD63 (as a marker of dense body secretion) were 
measured on platelets stimulated with three different aggregating agents, and the 
results compared with those using lumiaggregometry. There was a good agreement 
between lumiaggregometry and the results of the P-selectin testing, with diagnosis 
being concordant in 84% of cases [51,52]. 
 
In another study, P-selectin measurement using the P2Y12 kit identified a group of 
patients with acute coronary syndromes in whom high platelet reactivity was retained 
despite treatment with clopidogrel and were demonstrated to be at significantly higher 
risk of experiencing a further acute thrombotic event [53], thus demonstrating 
concordance between P-selectin measurements and other approaches to the 
measurements of platelet reactivity. Also it was demonstrated that treatment of patients 
with acute coronary syndromes with the P2Y12 antagonist prasugrel generates a higher 
degree of inhibition of P-selectin expression than clopidogrel except, interestingly, in 
patients with hypertension [54]. The P-selectin approach has also been used to assess 
platelet reactivity in patients with acute stroke [55]. The study demonstrated the effects 
of antiplatelet therapy being taken on admission with acute stroke on the 
measurements performed as part of the TARDIS study [Bath PM et al. Remote 
assessment of platelet function in patients with acute stroke or transient ischaemic 
attack, Submitted (2016)]. The approach has also been used to assess the residual 
effects of aspirin in surgical patients from whom this antiplatelet agent had been 
withdrawn [56]. The approach is also finding a use for determining the efficacy of 
antiplatelet agents in veterinary medicine [57]. 
 
Platelet activation leads to formation of platelet–leukocyte conjugates in whole blood, 
largely consequent to P-selectin on the surface of activated platelets interacting with a 
protein known as PSGL-1 on the leukocytes. Such conjugates can be quantitated using 
flow cytometry. For testing sites that do not have immediate access to such equipment, 
the use of a fixative such as AGGFix (Platelet Solutions Ltd) enables testing to be 
conducted remotely and then transferred to an appropriate laboratory for the flow 
cytometric analysis. Early results demonstrated increased levels of particularly 
platelet–monocyte conjugates in association with myocardial infarction [58]. Also the 
approach has been used to quantitate the effects of antiplatelet drug therapies 
in volunteers and in patients with stroke [59]. More recently, measurements of platelet 
aggregation and also platelet–leukocyte conjugate formation have been measured in 
parallel in the same blood samples in studies involving 96-well plate technology [40]. 
Parallel studies have also been performed on blood from mice [60]. In a recent review, it 
was considered that further studies are needed before platelet–leukocyte conjugate 
formation becomes routinely used in clinical practice [61]. 
 
Methods based on measurements of a cell metabolite 
 
A particular cell metabolite, the levels of which have been exploited as a means of 
studying platelet activation, is VASP. The level phosphorylated VASP (VASP-P) reflects 
the level of cyclic nucleotides in platelets (and other cells); in particular, it has been 
used as a means of determining the effects of agents that both increase and lower the 
level of cyclic AMP (cAMP) in platelets. cAMP is an important intracellular modulator of 
platelet reactivity with low levels supporting the platelet response and high levels being 
inhibitory. An important use of measurement of VASP phosphorylation has been in 
generating an assay for determining the effectiveness of clopidogrel acting as an 
antagonist at the P2Y12 receptors on platelets.  
 
One assay (Biocytex, Marseille, France) involves stimulating platelets with 
prostaglandin E1 (PGE1) to raise cAMP and then determining the ability of added ADP to 
lower that raised level of cAMP acting via the P2Y12 receptor. Good blockade of the 
receptor following clopidogrel administration, and thus high levels of VASP-P, implies 
effective treatment with clopidogrel. Because the level of VASP-P is controlled through 
ADP acting at the P2Y12 receptor and not by any other ADP receptor on the platelet, this 
approach is deemed to be the only current approach that selectively determines the 
effectiveness of clopidogrel acting via the 
P2Y12 receptor. In this particular assay, measurement of VASP-P involves 
permeabilization of platelets followed by flow cytometric assessment of the level of a 
fluorescent antibody directed at VASP-P inside the platelets. So, like many other 
approaches to the measurement of platelet reactivity, direct access to specialist 
laboratory facilities is required.  
 
Early studies were adjudged to compare very favorably with the VerifyNow and LTA 
approaches to assess the degree of inhibition brought about by clopidogrel or prasugrel 
administered to patients with acute coronary syndromes [62,63]. A recent successful 
application of this technology was to time the onset of P2Y12 receptor blockade after 
administration of prasugrel and ticagrelor in patients with acute coronary syndromes 
[64]. Very recently, a study was performed to directly compare the rate of formation of 
the active metabolite of clopidogrel in treated patients with the effects of the 
clopidogrel on platelet reactivity determined using the VASP assay and also MEA. It was 
concluded that the pharmacodynamics effects of the drug determined by the VASP 
measurements entirely reflected the pharmacokinetic measurements but that the 
results with MEA were disappointing in this regard [65]. 
 
More recently, another approach to measurement of VASP-P has been developed that 
utilizes VASPFix (Platelet Solutions Ltd), which provides a one-step approach to the 
measurement [66]. VASPFix includes a lytic agent, glass beads that bind the VASP from 
the lysed platelets and an appropriate fluorescent antibody to determine the level of 
VASP-P on the beads. The stability of the treated sample is such that after adding 
VASPFix to blood or PRP, the level of VASP-P is either determined directly using flow 
cytometry or the sample is frozen and analysed at a later time. Indeed the measurement 
is stable for several months after sample preparation. The approach has been used to 
assess platelet reactivity in patients taking clopidogrel or prasugrel with similar results 
being obtained to those using the Biocytex assay. In contrast to the use of PGE1 in the 
Biocytex assay, the VASPFix assay uses iloprost to raise cAMP in platelets. This is 
because it is now known that PGE1 acts at EP3 receptors on platelets, as well as the IP 
receptor, which acts to reduce VASP-P in the same way as ADP acting at the P2Y12 
receptor, and this appears to reduce the specificity of a test designed purely to 
investigate the effects of drugs acting at the P2Y12 receptor [66]. 
 
Other approaches to assessing platelet reactivity 
 
The Platelet Function Analyser (PFA)-100 involves passing whole blood at high shear 
stress through a capillary tube toward an aperture in a collagen-coated membrane, 
which contains either ADP or epinephrine. The time it takes to occlude this opening is 
defined as closure time. A high closure time is seen in patients with von Willebrand’s 
disease reflecting the importance of platelet adhesion to collagen in this particular 
assay. The assay that includes epinephrine is affected by aspirin treatment but, 
surprisingly the assay that includes ADP is relatively insensitive to P2Y12 antagonists 
[67,68]. The approach was deemed useful for determining inhibition of platelet function 
by aspirin but not clopidogrel when compared with the MEA [69]. 
 
To circumvent this lack of sensitivity to P2Y12 antagonists, an additional test cartridge 
(the INNOVANCE PFA P2Y test cartridge) was introduced in which the ADP is 
supplemented with PGE1. At least as judged by experiments performed in which a P2Y12 
antagonist was added to whole blood in vitro, the INNOVANCE PFA P2Y cartridge 
appears to be comparable to other currently available tests of platelet reactivity [70,71]. 
Also the test was able to identify some non-responders to clopidogrel, identified initially 
using other approaches, in some groups of volunteers and patients of treated with this 
drug [71,72]. A further report indicated its usefulness in identifying patients with 
congenital defective responses to ADP [73] and there is also a correlation with CYP450 
genotypes in clopidogrel-treated patients [74,75]. The sensitivity of the test is markedly 
influenced by the nature of the anticoagulant used in obtaining the blood for analysis 
[70] and it is likely that this should be taken account of in any future studies. 
Incidentally, a focus on the implications of the anticoagulant used in testing of platelet 
reactivity globally is a matter that still requires close attention. For example, the 
MEA currently recommends the use of hirudin in preference to citrate for testing the 
effectiveness of P2Y12 antagonists where citrate seems toreduce the degree of inhibition 
of platelet reactivity brought about by such agents [76]. Also, very recently, potential 
problems have been identified in the routine use of citrate in the VerifyNow assay for 
measurements performed at a time point very close to venepuncture, which appear to 
be caused by a ‘stunning’ effect of the citrate on platelet reactivity [77]. 
 
Thrombelastography (TEG; Haemonetics Corporation, MA, USA) is a global test of 
thrombosis, which measures aspects of clot formation in a specially designed device. 
There were some early encouraging results when ADP-induced platelet–fibrin clot 
strength was used to serve as a predictor of either ischemic events or bleeding in 
clopidogrel-treated patients poststenting [78]. However, the approach is still not widely 
used for studies of platelet reactivity and in a recent study, the TEG results were found 
not to correlate well with the VerifyNow approach [79]. On the other hand, an 
adaptation known as short TEG has recently been used to assess the impact of aspirin 
and clopidogrel in patients with stent thrombosis and to modify treatments on the basis 
of the results obtained [80,81]. In addition, the first report of the TEG-6S system has just 
been published, which is claimed to offer a point-of-care approach to TEG [82]. So far 
the studies are not large enough for the full impact of these new approaches to be 
assessed, but there does appear to be some promise here. 
 
Aggreguide (Aggredyne, Inc., TX, USA) is a new point-of-care testing procedure based on 
light scattering technology that is in the very early stages of evaluation. While it appears 
to be attractive and easy to use, the first published study in cardiovascular patients 
showed poor reproducibility with other tests of platelet reactivity [83]. 
 
Final considerations 
 
There are many different approaches to assessing platelet reactivity. Here, the focus has 
been on measurements of platelet aggregation using variety of different approaches and 
on the use of platelet activation markers and a particular cell metabolite. Although not 
discussed in detail in this review, it is generally considered that the comparability of 
different testing procedures is sometimes quite disappointing [84]. However, this is 
against a background of a huge number of variations in the detailed methodologies 
employed within any one of the approaches used, and uncertainties about the 
positioning of cutoffs between values that are deemed acceptable andthose that are not. 
Our own experience in developing the newer remote assays based on measurement of 
P-selectin is that these appear to compare reasonably well with the other technologies 
for identification of patients with platelet dysfunction [51,52] and also when comparing 
results obtained for patients taking aspirin, clopidogrel or prasugrel [49]. 
 
One of the main problems with platelet function testing in general is the need for 
specialist equipment and expertise in close proximity to the blood sampling. However, 
some progress is now being made in the use of fixatives that provide the option of 
remote testing with no requirement for equipment and expertise at the testing site. 
 
Future perspective 
 
Platelet reactivity is measured in freshly prepared blood and historically has relied on 
the availability of specialized equipment and technical expertise for the measurements 
to be performed. But recent advances mean that measurement of platelet reactivity is 
becoming easier. Blood can be activated, stabilized and sent away for analysis without 
any need for equipment or special expertise at the point of blood sampling. It is 
anticipated that this will make it easier to assess platelet function in relation to bleeding 
diatheses consequent to congenital or drug-induced platelet hypoactivity, and also to 
determine high residual platelet reactivity in patients who are at risk of conditions such 
as heart attack and stroke, often despite drug treatment. Effective titration of drug 
treatment could then be a real possibility with more effective P2Y12 antagonists such as 
prasugrel or ticagrelor used in place of clopidogrel in all patients who need this, and 
possibly clopidogrel used in place of the more effective agents to avoid bleeding. 
 
Conclusion 
 
An overall assessment of current and future approaches to assessing platelet reactivity 
is provided in Table 1. The table summarizes the various approaches available and 
identifies their main advantages and disadvantages. It can be seen that measurements 
of platelet aggregation are gradually giving way to alternative userfriendly 
methodologies that provide similar information on the degree of platelet activation in a 
blood sample from individual patients that can be used for diagnostic and drug 
monitoring purposes. The use of flow cytometry with fixation, which enables remote 
platelet testing, is moving forward rapidly, while some of the very new approaches 
require further validation before they will find a place in routine practice. 
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Table 1 
Approaches to assessment of platelet reactivity. 
Abbreviations: LTA: light transmission aggregometry; MEA: multiple electrode 
aggregometry; PFA: platelet function analyser; PRP: platelet-rich plasma; TEG: 
thrombelastography; VASP: vasodilator-stimulated phosphoprotein 
 
Approach Method/ 
equipment 
Advantages Disadvantages 
    
LTA Aggregometer 
 
 
 
 
 
 
 
 
 
Optimul assay 
Considered to be 
the gold standard. 
Formation of 
visible platelet 
aggregates accords 
with hemostatic 
plug and thrombus 
formation. Wide 
range of uses. 
 
96-well format 
enables large 
number of samples 
to be assessed in 
parallel 
Potential wide 
range of uses. 
Performed in PRP. 
Centrifugation 
required. Platelet 
counts vary. 
Prompt access to 
laboratory facilities 
and technical 
expertise required. 
 
 
As for LTA 
Platelet 
aggregation in 
whole blood 
MEA 
 
 
 
 
 
 
 
VerifyNow 
 
 
 
 
 
 
 
 
Use of whole blood 
considered to be 
more physiological 
than use of PRP. 
No centrifugation 
required. Wide 
range of uses. 
 
Use of whole blood 
considered to be 
more physiological 
than use of PRP. 
Measurements 
require availability 
of special 
equipment but 
Prompt access to 
laboratory 
facilities and 
technical expertise 
required 
 
 
 
Specifically 
designed to 
monitor 
efficacy of 
antiplatelet agents 
and thus not 
designed for other 
uses. Disappointing 
clinical outcomes 
 
 
 
 
Platelet counting 
minimal technical 
expertise is 
required. Point-of-
care testing.  
 
Use of whole blood 
considered to be 
more physiological 
than use of PRP. 
Fixation of blood 
samples can negate 
the need for 
immediate platelet 
counting and can 
enable remote 
testing. Wide range 
of uses. 
when used to tailor 
treatment with 
antiplatelet agents.   
 
A commercial 
version of the test 
(Plateletworks) 
requires immediate 
access to 
equipment for 
platelet counting. 
Platelet activation 
markers 
Flow cytometry, 
e.g., P-selectin 
 
 
 
 
 
 
 
 
 
 
Flow cytometry, 
e.g., platelet– 
leukocyte 
conjugates 
Fixation of blood 
samples can negate 
the need for 
immediate flow 
cytometric analysis 
and can enable 
remote testing. No 
stirring or agitation 
of the blood is 
needed. Wide range 
of uses. 
 
Fixation of blood 
samples can negate 
the need for 
immediate flow 
cytometric analysis 
and can enable 
remote 
testing 
A 96-well format 
can be used to 
agitate the blood 
samples 
Wide range of uses 
When used without 
fixation immediate 
access to flow 
cytometry facilities 
is required. 
 
 
 
 
 
 
 
When used without 
fixation immediate 
access to flow 
cytometry facilities 
is required. 
Cell metabolites Flow cytometry, 
e.g., VASP 
phosphorylation 
VASP 
phosphorylation 
reflects cyclic 
nucleotide levels in 
Platelets. Can be 
used to assess 
efficacy of P2Y12 
One approach (use 
of the Biocytex 
assay) requires 
immediate access 
to flow cytometry. 
antagonists. One 
approach (use of 
VASPFix) allows 
frozen samples to 
be stored to enable 
remote testing. 
Other approaches PFA 
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Aggreguide 
An assay based on 
platelet adhesion to 
collagen under high 
shear. 
Measurements 
require availability 
of special 
equipment but 
minimal technical 
expertise is 
required. Point-of-
care testing. The 
INNOVANCE PFA 
P2Y cartridge 
appears to provide 
an improved means 
of testing for effects 
of P2Y12 
antagonists. 
 
Deemed to provide 
a global test of 
thrombosis based 
on clot formation. 
Newer adaptations 
of the methodology 
show promise. 
 
Measurement of 
platelet 
aggregation based 
on light scattering 
technology. 
Further studies are 
needed with 
the INNOVANCE 
PFA P2Y cartridge 
to define the 
usefulness of the 
approach. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Further studies are 
needed to define 
the usefulness of 
the approach. 
 
 
 
 
Still in the early 
stages of 
Development. 
 
 
Executive summary 
 
Platelet reactivity: what is it & why study it? 
 
 Platelet reactivity is a broad term indicating the response of blood platelets to an 
external stimulus, usually an ‘aggregating agent’. 
 Platelets play a role in the hemostatic process and also contribute to generation 
of a thrombus that can block a blood vessel leading heart attack or stroke. 
 
 A pronounced platelet response is associated with an increased risk of 
thrombosis and a low platelet response is associated with bleeding and bruising. 
 
 Detection of high residual platelet activity despite treatment with antiplatelet 
agents helps predict future ischemic events. 
 
 Identification of deficiencies in platelet function explains why some individuals 
are subject to enhanced bleeding or bruising. 
 
 Excessive inhibition of platelet reactivity in patients treated with antiplatelet 
agents can also be associated with excessive bleeding with implications for 
surgical interventions in those patients. 
 
 There is now the concept of using measurements of platelet reactivity to identify 
a ‘therapeutic window’ in patients receiving antiplatelet agents, so as to optimize 
a reduction in risk of a thrombotic event without increasing the risk of bleeding. 
 
Approaches to assessment of platelet reactivity 
 
 Measurement of platelet aggregation in platelet-rich plasma using light 
transmission aggregometry (LTA) is considered to be the ‘gold standard’ for 
measurement of reactivity but is complex and technically demanding. 
 
 Measurement of platelet aggregation in whole blood using Multiplate Electrode 
Aggregometry (MEA), the VerifyNow approach and by platelet counting is 
deemed to be more physiological than studies performed in platelet-rich plasma. 
 
 Measurement of platelet activation markers including P-selectin provides an 
alternative approach to measuring platelet reactivity and this introduces the 
concept of ‘remote’ platelet testing. 
 
 Phosphorylation of vasodilator-stimulated phosphoprotein (VASP) provides 
another approach that has found value particularly in assessing the impact of 
P2Y12 antagonists on platelet reactivity. Methods based on measurements of 
platelet aggregation. 
 
Light transmission aggregometry: 
 
 Used in identifying deficiencies in platelet aggregation in association with 
enhanced bruising and bleeding. 
 
 Used in quantitating the pharmacological effects of antiplatelet agents. 
 
 There are positive examples of the use of LTA in determining the variable effects 
of the P2Y12 antagonist clopidogrel and in considering the implications for re-
thrombosis and bleeding. 
 
Multiplate electrode aggregometry: 
 
 Generally data obtained using MEA compare favorably with LTA. 
 
 There are positive examples of the use of MEA for guiding antiplatelet therapy. 
 
VerifyNow: 
 
 Generally data obtained using VerifyNow compare favorably with LTA and MEA, 
and the advantage of VerifyNow is that little technical expertise is required. 
 
 Clinical trials of using VerifyNow to guide the use of P2Y12 antagonists as 
antiplatelet therapy have been unsuccessful so far in terms of improving clinical 
outcomes. 
 
Platelet counting: 
 
 Plateletworks provides a commercially available means of measuring platelet 
aggregation in whole blood by platelet counting and there are some positive 
comparisons with LTA. 
 
 There are potential benefits of fixation of platelets prior to platelet counting that 
have already proved useful in platelet research. 
 
Methods based on measurements of platelet activation markers 
 
 Measurements of P-selectin as a means of studying platelet reactivity include 
studies in cardiology, stroke, surgery and veterinary medicine. 
 
 The P-selectin approach offers the advantage of remote platelet testing with no 
need for a laboratory or special technical expertise available close to the point of 
blood testing. 
 
 A consequence of P-selectin expression on platelets in whole blood is platelet–
leukocyte conjugate formation, which can be quantified in parallel with 
measurements of platelet aggregation. 
 
Methods based on measurements of a cell metabolite 
 
 Measurement of the phosphorylation of VASP provides a convenient means of 
measuring the effects on platelets of agents that modify cyclic AMP, including 
P2Y12 antagonists. 
 
 The Biocytex approach involves permeabilizing platelets and measuring VASP-P 
by flow cytometry. 
  The VASPFix approach is a one-step approach that can be used remotely without 
the immediate availability of a flow cytometer. 
 
Additional approaches to assessing platelet reactivity 
 
 The platelet function analyzer (PFA)-100 is easy to use device that is based on 
platelet adhesion to collagen. 
 
 The introduction of the INNOVANCE PFA P2Y test cartridge for use in the PFA is 
being tested with some positive outcomes in assessment of the effects of ADP on 
platelets and the inhibitory effects of P2Y12 antagonists. 
 
 Thrombelastography measures platelet–fibrin clot formation and has found 
some application in the studies of platelet reactivity. 
 
 Newer approaches to thrombelastography are being introduced and assessed for 
measurement of platelet reactivity. 
 
 Aggreguide is a new approach to testing that is based on the light scattering 
properties of aggregating platelets that is now starting to be assessed for its 
usefulness in the research and clinical practice. 
